Affimed Analyst Ratings
Affimed Analyst Ratings
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price Affimed (AFMD) is trading at is $0.31, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 1492.36% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 09/25/2023 | 2129.3% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 09/12/2023 | 2129.3% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 09/07/2023 | 2129.3% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 1810.83% | Truist Securities | $8 → $6 | Maintains | Buy |
| 08/11/2023 | 1492.36% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/08/2023 | 1810.83% | Berenberg | → $6 | Assumes | → Buy |
| 06/05/2023 | 1492.36% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 05/24/2023 | 1810.83% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/27/2023 | 2129.3% | Wells Fargo | → $7 | Assumes | → Overweight |
| 03/24/2023 | 218.47% | Stifel | $2 → $1 | Maintains | Hold |
| 03/24/2023 | 1810.83% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 12/12/2022 | 2129.3% | Wells Fargo | $8 → $7 | Maintains | Overweight |
| 12/12/2022 | 1810.83% | Piper Sandler | $7 → $6 | Maintains | Overweight |
| 12/12/2022 | 1810.83% | SVB Leerink | $10 → $6 | Maintains | Outperform |
| 12/12/2022 | 1810.83% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 10/10/2022 | 536.94% | Stifel | $9 → $2 | Downgrades | Buy → Hold |
| 06/23/2022 | 2766.24% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 03/31/2022 | 2129.3% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 3721.66% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 10/21/2021 | 3084.71% | Truist Securities | → $10 | Initiates Coverage On | → Buy |
| 10/12/2021 | 3721.66% | SVB Leerink | $13 → $12 | Maintains | Outperform |
| 09/30/2021 | 3721.66% | Stifel | → $12 | Initiates Coverage On | → Buy |
| 03/31/2021 | 4677.07% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 03/24/2021 | 4677.07% | Wells Fargo | $10 → $15 | Maintains | Overweight |
| 03/11/2021 | 4358.6% | SVB Leerink | $9 → $14 | Maintains | Outperform |
| 11/11/2020 | 2766.24% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 06/24/2020 | 2447.77% | SVB Leerink | $7 → $8 | Maintains | Outperform |
| 03/28/2019 | 2447.77% | SVB Leerink | → $8 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 1492.36% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 09/25/2023 | 2129.3% | 坎託·菲茨傑拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 09/12/2023 | 2129.3% | 坎託·菲茨傑拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 09/07/2023 | 2129.3% | 坎託·菲茨傑拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 08/11/2023 | 1810.83% | Truist 證券 | 8 美元 → 6 美元 | 維護 | 買 |
| 08/11/2023 | 1492.36% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 08/08/2023 | 1810.83% | 貝倫貝格 | → 6 美元 | 假設 | → 購買 |
| 06/05/2023 | 1492.36% | HC Wainwright & Co. | 6 美元 → 5 美元 | 維護 | 買 |
| 05/24/2023 | 1810.83% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 03/27/2023 | 2129.3% | 富國銀行 | → 7 美元 | 假設 | → 超重 |
| 2023 年 3 月 24 日 | 218.47% | Stifel | $2 → $1 | 維護 | 保持 |
| 2023 年 3 月 24 日 | 1810.83% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 2022 年 12 月 12 日 | 2129.3% | 富國銀行 | 8 美元 → 7 美元 | 維護 | 超重 |
| 2022 年 12 月 12 日 | 1810.83% | 派珀·桑德勒 | 7 美元 → 6 美元 | 維護 | 超重 |
| 2022 年 12 月 12 日 | 1810.83% | SVB Leerink | 10 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 2022 年 12 月 12 日 | 1810.83% | HC Wainwright & Co. | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 10 月 10 日 | 536.94% | Stifel | 9 美元 → 2 美元 | 降級 | 買入 → 持有 |
| 06/23/2022 | 2766.24% | SVB Leerink | 10 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 03/31/2022 | 2129.3% | 派珀·桑德勒 | → 7 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2022 年 2 月 23 日 | 3721.66% | 坎託·菲茨傑拉德 | → 12 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 10 月 21 日 | 3084.71% | Truist 證券 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 12 月 10 日 | 3721.66% | SVB Leerink | 13 美元 → 12 美元 | 維護 | 跑贏大盤 |
| 09/30/2021 | 3721.66% | Stifel | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 3 月 31 日 | 4677.07% | 瑞士信貸 | → 15 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 3 月 24 日 | 4677.07% | 富國銀行 | 10 美元 → 15 美元 | 維護 | 超重 |
| 03/11/2021 | 4358.6% | SVB Leerink | 9 美元 → 14 美元 | 維護 | 跑贏大盤 |
| 11/11/2020 | 2766.24% | SVB Leerink | 8 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 06/24/2020 | 2447.77% | SVB Leerink | 7 美元 → 8 美元 | 維護 | 跑贏大盤 |
| 03/28/2019 | 2447.77% | SVB Leerink | → 8 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Affimed (AFMD)?
Affimed（AFMD）的目標價格是多少？
The latest price target for Affimed (NASDAQ: AFMD) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $5.00 expecting AFMD to rise to within 12 months (a possible 1492.36% upside). 16 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月15日公佈了Affimed（納斯達克股票代碼：AFMD）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計AFMD將在12個月內升至12個月內（可能上漲1492.36％）。去年有16家分析公司公佈了評級。
What is the most recent analyst rating for Affimed (AFMD)?
分析師對 Affimed (AFMD) 的最新評級是多少？
The latest analyst rating for Affimed (NASDAQ: AFMD) was provided by HC Wainwright & Co., and Affimed reiterated their buy rating.
HC Wainwright & Co. 對Affimed（納斯達克股票代碼：AFMD）的最新分析師評級由HC Wainwright & Co. 提供，Affimed重申了買入評級。
When is the next analyst rating going to be posted or updated for Affimed (AFMD)?
Affimed（AFMD）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Affimed的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Affimed的最新評級是在2023年11月15日公佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Affimed (AFMD) correct?
分析師評級申明 (AFMD) 是否正確？
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price Affimed (AFMD) is trading at is $0.31, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Affimed（AFMD）評級，目標股價爲0.00美元至5.00美元。Affimed（AFMD）目前的交易價格爲0.31美元，在分析師的預測區間內。
